Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/5-MeO-DMT/Neuroimaging & Brain Measures

5-MeO-DMT for Neuroimaging & Brain Measures

6 papers and 1 clinical trial exploring 5-meo-dmt as a treatment for neuroimaging & brain measures.

CompoundTryptamine

5-MeO-DMT

A potent tryptamine psychedelic known for profound mystical experiences, currently under clinical investigation for TRD and anxiety.

Full 5-MeO-DMT profile
IndicationApproximately 264 million people globally suffer from depression, with PTSD affecting around 8 million adults in the United States each year.

Neuroimaging & Brain Measures

Recent advances in neuroimaging have shed light on the neurobiological mechanisms underlying the effects of psychedelics, particularly in the treatment of mental health disorders such as depression and PTSD. Studies involving compounds like psilocybin and MDMA have demonstrated significant changes in brain activity associated with therapeutic outcomes.

Full Neuroimaging & Brain Measures profile

Academic Research

6 papers
Open Accessindividual

Complex slow waves in the human brain under 5-MeO-DMT

This naturalistic EEG study (n=29) examines the effects of inhaled synthetic 5-MeO-DMT (12mg) on brain activity in healthy individuals. It finds that 5-MeO-DMT radically reorganises low-frequency neural activity flows, making them incoherent, heterogeneous, and nonrecurring. It also causes broadband activity to exhibit slower, more stable, low-dimensional behaviour with increased energy barriers to rapid global shifts.

Published
August 1, 2025
Journal
Cell Reports
Authors
Blackburne, G., Mcalpine, R. G., Fabus, M., Liardi, A., Kamboj, S. K., Mediano, P. A. M., Skipper, J. I.
Paywallindividual

Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study

This Phase I clinical trial (n=36) of sublingual 5-MeO-DMT (6-12 mg weekly doses over four weeks) in adults with moderate to high anxiety/depression demonstrated good safety and tolerability with no significant adverse events, rapid absorption with peak plasma concentrations at 20 minutes, dose-dependent neurophysiological modulation without full psychedelic effects, and maintenance of normal cognitive and behavioral function.

Published
July 15, 2025
Journal
Neuropsychopharmacology
Authors
Beatriz, M., Millón, B., Noguera, L., Bruno, D., Vita, L., Zanino, M., Kassuha, D. E., Ortiz, J. E., Feresin, G. E., Díaz-Dellavalle, P., Orosco, L., Garcés, M. A., Diez, P., Albarracín, S. G., Bruno, M. A.
Open Accessindividual

Exploring 5-MeO-DMT as a pharmacological model for deconstructed consciousness

In an exploratory observational study using micro-phenomenological interviews, psychometric questionnaires and EEG in naturalistic ceremonial settings, the authors show that 5‑MeO‑DMT can produce a progressive deconstruction of selfhood — in extreme cases a complete absence of self-experience and other phenomenal content with preserved awareness — accompanied by global alpha and posterior beta power reductions consistent with inhibition of top‑down models. The findings support 5‑MeO‑DMT as a pharmacological model for deconstructed consciousness while noting methodological limitations and the need for controlled, real‑time and phenomenologically trained studies.

Published
April 21, 2025
Journal
Neuroscience of Consciousness
Authors
Timmermann, C., Sanders, J. W., Reydellet, D., Barba, T., Luan, L. X., Soto Angona, Ó., Ona, G., Allocca, G., Smith, C. H., Daily, Z. G., Mason, N. L., Kloft-Heller, L., Kuchar, M., Janeckova, L., Palenicek, T., Erritzoe, D., Ramaekers, J. G., Carhart-Harris, R. L., Uthaug, M. V.
Open Accessmeta

The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action

This review (2024) examines the potential therapeutic mechanisms of action for alcoholism (AUD) treatment using 5-MeO-DMT. It highlights that 5-MeO-DMT can induce mystical experiences and ego-dissolution, leading to increased psychological flexibility and mindfulness, which may alleviate AUD symptoms. Additionally, preliminary evidence suggests that 5-MeO-DMT modulates neural oscillations and exhibits neuroplasticity and anti-inflammatory properties, indicating its potential clinical implications for AUD and related psychiatric comorbidities.

Published
April 10, 2024
Journal
Addiction Biology
Authors
Tap, S. C.
Open Accessindividual

“Paradoxical wakefulness” induced by psychedelic 5-methoxy-N,N-dimethyltryptamine in mice

This pre-print mice study finds that 5-MeO-DMT delayed the onset of REM sleep as measured with EEG, and showed behavioural signals (e.g. head twitches) consistent with psychedelic effects, whilst during the waking stage the EEG measures were also showing signs of REM sleep (paradoxical wakefulness).

Published
December 11, 2022
Journal
Biorxiv
Authors
Breant, B., Mengual, J. P., Bannerman, D., Sharp, T., Vyazovskiy, V. V.
Paywallindividual

A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder

This case report SPECT imaging study explored the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder (AUD). It reported that the patient felt improvement in mood, cessation of alcohol use, and decreased cravings at 5 days post-treatment, but the patient returned partially to mild alcohol use at 2 months. Also, higher perfusion in multiple brain regions broadly associated with AUD and known pharmacology of both compounds was reported.

Published
January 1, 2018
Journal
Progress in Brain Research
Authors
Barsuglia, J. P., Polanco, M., Palmer, R., Malcolm, B. J., Kelmendi #, B., Calvey, T.

Clinical Trials

1 trial
Not yet recruitingPhase I

Effects of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) administered by intramuscular injection on frequency oscillatory power bands in healthy adults

Single-blind, non-randomised, single-group repeated-measures study (n=15) testing IM 5‑MeO‑DMT (3, 6, 9 mg) and saline placebo across four sessions to assess MEG/fMRI markers and wellbeing.

Started
September 1, 2023
Type
interventional
Blinding
single
Randomized
No
Registry ID
ACTRN12623000884606

Explore further

Search all 5-MeO-DMT papers Search all Neuroimaging & Brain Measures trials Full 5-MeO-DMT profile Full Neuroimaging & Brain Measures profile